chevron-down Created with Sketch Beta.
May 19, 2023

Phase 1 Trial Shows Promising Use of Vaccines in Patients with Pancreatic Cancer

On May 10, 2023, researchers from Memorial Sloan Kettering Cancer Center published results from a phase 1 clinical trial of the use of Messenger RNA vaccines (used to prevent or lessen the impact of COVID-19 infection) in treating patients with pancreatic cancer following resection of their tumors.  Post-surgical treatment that included the vaccines triggered a robust immune response that delayed the recurrence of patients’ pancreatic cancer.  The next steps include conducting a much larger and randomized clinical trial across multiple locations beginning summer 2023.

Entity:
Topic:
The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.